As the European markets navigate mixed economic data and geopolitical developments, investor interest in technology stocks is buoyed by strong AI-related earnings. Against this backdrop, growth companies with significant insider ownership can offer a unique perspective on potential investment opportunities, as they often align management interests with those of shareholders.
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.6% |
| MilDef Group (OM:MILDEF) | 10.3% | 30.9% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 58.6% |
| KebNi (OM:KEBNI B) | 11.8% | 105.2% |
| Gold Road International (OB:GOLDR) | 35.9% | 89.8% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 60.7% |
| CD Projekt Red (WSE:CDR) | 35.2% | 40.1% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★★★
Overview: Envipco Holding N.V. develops, manufactures, assembles, leases, sells, markets, and services reverse vending machines in North America and Europe with a market cap of €244.53 million.
Operations: Envipco Holding N.V. generates revenue through the development, manufacturing, assembly, leasing, sales, marketing, and servicing of reverse vending machines across North America and Europe.
Insider Ownership: 15.4%
Envipco Holding, despite recent financial losses, shows promise as a growth company with substantial insider ownership. The company has secured significant contracts for reverse vending machines in the UK, which could bolster future revenue. Insiders have been buying shares recently, indicating confidence. Although it was dropped from the Netherlands ASCX AMS Small Cap Index and faces high share price volatility, its expected revenue growth of 30.5% annually surpasses market averages.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery globally with a market cap of NOK4.59 billion.
Operations: The company's revenue is primarily derived from its own products, amounting to NOK662.92 million, and third-party products, contributing NOK89.92 million.
Insider Ownership: 10.2%
Medistim is demonstrating solid growth potential, with forecasted revenue and earnings growth rates of 8.9% and 11.8% per year, respectively, surpassing the Norwegian market averages. The company recently reported strong financial results for Q2 2026, with sales reaching NOK 202.03 million and net income at NOK 52.2 million, both showing significant year-on-year increases. Trading below estimated fair value by 17.5%, Medistim's high insider ownership aligns with its robust financial performance outlook.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Samhällsbyggnadsbolaget i Norden AB (publ) owns, develops, and manages residential and social infrastructure properties across Sweden, Norway, Finland, and Denmark with a market cap of SEK5.82 billion.
Operations: The company generates revenue from its operations in residential and social infrastructure properties across Sweden, Norway, Finland, and Denmark.
Insider Ownership: 20.9%
Samhällsbyggnadsbolaget i Norden is forecast to achieve significant revenue growth at 34.2% annually, outpacing the Swedish market. Despite current financial challenges, with a net loss of SEK 678 million for H1 2026, its profitability outlook over the next three years remains positive. Recent leadership changes may influence strategic direction as Andreas Morfiadakis takes over as CEO. The company trades at good value compared to peers, though interest payments are not well covered by earnings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com